AstraZeneca’s Covid-19 vaccine showed 79 per cent efficacy against symptomatic disease and 100 per cent efficacy against severe disease and hospitalisation in a new, US-based clinical trial, the company said Monday. The findings from the new Phase 3 trial, which included more than 32,000 participants, may boost confidence in the vaccine, which was originally developed by the University of Oxford, as reported by CNN.

The trial showed that the vaccine was well-tolerated and identified no safety concerns, the company said. An independent committee “found no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine”, according to AstraZeneca. The new data came from a Phase 3 clinical trial conducted in the US, Chile, and Peru.